Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
June 28, 2022
CGD has set up a working group to examine different ways to purchase antimicrobials in LMICs in order to identify actionable policies to improve access and stewardship for key products and increase funding for research into new ones. We are launching today the Working Group’s first working paper.
Blog Post
April 07, 2022
While oral antivirals are not a substitute for vaccination, they help prevent severe illness, save lives, and preserve health systems. Vaccination rates continue to lag in low-income countries: only 14 percent of the population in low-income countries has received one dose of the vaccine, compared t...